Emerging treatments
High-dose rifampicin regimens
Higher doses of rifampicin have been associated with improved clinical response. In one randomised controlled trial, patients treated with high-dose rifampicin plus standard-dose doxycycline had significantly higher clinical response rates compared with patients treated with standard-dose rifampicin and standard-dose doxycycline, (95% versus 82%), without further adverse effects. These findings need to be confirmed in future studies before higher doses of rifampicin are recommended.[139]
Hydroxychloroquine-based regimens
Hydroxychloroquine, an antiprotozoal agent often used for the treatment of malaria, has been shown to improve the efficacy of the doxycycline plus streptomycin regimen in clinical trials, as well as reduce the risk of relapse. However, further research is required.[140][141]
Use of this content is subject to our disclaimer